Can-Fite BioPharma Ltd. (CANF)
| Previous Close | 2.3000 |
| Open | 2.2301 |
| Bid | 2.2400 x 1000 |
| Ask | 2.3000 x 1100 |
| Day's Range | 2.2400 - 2.2998 |
| 52 Week Range | 2.1500 - 12.9000 |
| Volume | |
| Avg. Volume | 78,788 |
| Market Cap | 8.142M |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.7900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.25 |
- Business Wire
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
PETACH TIKVA, Israel, March 16, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that Dr. Sari Fishman, the Company’s Vice President of Business Development, will participate in the BIO-Europe Spring® partnering conference in Basel, Switzerland from March 20 to 22, 2023. Dr. Fishman will conduct one-on-one meetings with a substantial nu
- Business Wire
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
PETACH TIKVA, Israel, March 13, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that patients with decompensated cirrhosis, an advanced form of cirrhosis associated with liver failure for which there are no therapeutic options other than liver transplantation, will be treated with Namodenoson at the Soroka Medical Center in Israel unde
- Business Wire
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
PETACH TIKVA, Israel, February 14, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Purinergic Signalling, a peer-reviewed scientific journal focused on molecules which target adenosine receptors, published an article titled "Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotecti
